Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Biochimica Et Biophysica Acta|January 14, 2012
TET2, a tumor suppressor in hematological disordersThomas Mercher, Cyril Quivoron, Lucile Couronné, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 2, 2016
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applicationsVianney Poinsignon, Lionel Mercier, Koïchi Nakabayashi, et al.
Stem Cell Research & Therapy|June 17, 2022
Endothelial and hematopoietic hPSCs differentiation via a hematoendothelial progenitorAlejandra Vargas-Valderrama, Anne-Charlotte Ponsen, Morgane Le Gall, et al.
Blood Advances|March 28, 2018
B-cell tumor development in <i>Tet2</i>-deficient miceEnguerran Mouly, Hussein Ghamlouch, Veronique Della-Valle, et al.
Hemasphere|August 23, 2021
Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast CancersSabine Khalife-Hachem, Khalil Saleh, Florence Pasquier, et al.
The Journal of Liquid Biopsy|March 3, 2025
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experienceClaudia Parisi, José Carlos Benitez, Hélène Lecourt, et al.
Cancer Cell|July 5, 2011
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesisCyril Quivoron, Lucile Couronné, Véronique Della Valle, et al.
Nature Medicine|July 18, 2018
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenibLynn Quek, Muriel D David, Alison Kennedy, et al.
Pageof 2